Liberation and cancer are completely given tumors through the super -charging the immune system

To meet this unparalleled medical need, researchers at the University of California School of Medicine San Diego explore new methods to improve the effectiveness of HNSCC treatments. In a new study of oral cancer, a type of HNSCC, they explain how two timing can specifically two different remedies to improve the results of treatment by protecting the lymphoma -made lymph numbers, which are located near tumors and has an important role in mediation in the response of the immune system of the tumor.

The researchers found:

• In oral cancer mice, the provision of radiotherapy that maintains the lymph nodes that lead the tumor after that, which led to a complete and permanent response to the tumor, which means that the tumors have become unspecified. This happened on 15/20 mice treated with this approach.
• The two therapies are decorated to enhance the deportation of a specific type of immune cell, and the cccr 7 stimulant cells are called from the tumors to the lymph nodes. These cells have helped run a stronger immune response to the tumor. This happened in all treated mice.

The results of the study can have significant effects on HNSCC therapy, as well as other resistance or non -response cancers of the current standard treatment approach. Research also provides a valuable biological vision of the role of lymph nodes that lead the tumor in cancer biology, which can have other effects on developing new treatments. Although it will take further research to explore the entirely specific treatment approach capabilities, the results show the importance of improving the sequence and timing of treatments to increase their interest in the patient. Researchers are now conducting clinical experiments in cooperation with researchers at the Provence Chelse Cancer Center to take advantage of these strategies to improve results in head and neck cancer patients.

The study, published in Nature CommunicationsRobert Sadodawi Konvka, PhD in Medicine, PhD, PGY-8, resident doctor and Joseph Califano, PhD in Medicine, Professor and Temporary Chairman in the Department of Specific Science Fashion System, Wris, Matthew Strauss, Speaker of the Parliament at the Faculty of Medicine at UC. Califano is also the director of the Hanna Center and Mark Gilbarman Cancer and Neck at Moore Cancer Center. The study was supported, partly by the National Cancer Institute, with the funding of the R01 grant led. Califano and Andrew Charraby, PhD in PhD, Associate Professor and President of Jacobs, Advisor to the Department of Radiation and Applied Sciences at the University of California Medicine in San Diego, as well as a member of the Head and Neck Cancer Center at the Morris Cancer Center. The authors do not announce any competing interests.